HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis.

AbstractBACKGROUND:
Male breast cancer is a rare malignancy. Despite the lack of prospectively generated data from trials in either the adjuvant or metastatic setting, patients are commonly treated with hormone therapies. Much controversy exists over the use of gonadotropin-releasing hormone analogues in metastatic male breast cancer patients. We conducted this study to provide more concrete ground on the use of gonadotropin-releasing hormone analogues in this setting.
METHODS:
We herein present results from a pooled analysis including 60 metastatic male breast cancer patients treated with either an aromatase inhibitor or cyproterone acetate as a monotherapy (23 patients) or combined with a gonadotropin-releasing hormone analogue (37 patients).
RESULTS:
Overall response rate was 43.5% in patients treated with monotherapy and 51.3% with combination therapy (p = 0.6). Survival outcomes favored combination therapy in terms of median progression-free survival (11.6 months versus 6 months; p = 0.05), 1-year progression-free survival rate (43.2% versus 21.7%; p = 0.05), median overall survival (29.7 months versus 22 months; p = 0.05), and 2-year survival rate (64.9% versus 43.5%; p = 0.05).
CONCLUSIONS:
In metastatic male breast cancer patients, the combined use of gonadotropin-releasing hormone analogues and aromatase inhibitors or antiandrogens seems to be associated with greater efficacy, particularly in terms of survival outcomes, compared with monotherapy. Collectively, these results encourage considering these agents in the metastatic setting.
AuthorsLuigi Di Lauro, Laura Pizzuti, Maddalena Barba, Domenico Sergi, Isabella Sperduti, Marcella Mottolese, Carla Azzurra Amoreo, Franca Belli, Patrizia Vici, Valerie Speirs, Daniele Santini, Ruggero De Maria, Marcello Maugeri-Saccà
JournalJournal of hematology & oncology (J Hematol Oncol) Vol. 8 Pg. 53 (May 17 2015) ISSN: 1756-8722 [Electronic] England
PMID25980944 (Publication Type: Journal Article)
Chemical References
  • Aromatase Inhibitors
  • Gonadotropin-Releasing Hormone
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Aromatase Inhibitors (metabolism)
  • Breast Neoplasms, Male (drug therapy)
  • Female
  • Gonadotropin-Releasing Hormone (analogs & derivatives)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: